References:

  • 1.Smith S et al. Atopic dermatitis in adults: an Australian management consensus. Australas J Dermatol 2020; 61(1): 23–32.
  • 2.Guttman-Yassky E et al. New era of biologic therapeutics in atopic dermatitis. Expert Opin Biol Ther 2013;13(4):549–61.
  • 3.National Health Service (NHS) UK. Atopic eczema. Available at www.nhs.uk/conditions/atopic-eczema (accessed June 2020).
  • 4.Eichenfield LF et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol 2014;70(2):338–51.
  • 5.Leung DYM et al. New insights into atopic dermatitis. J Clin Invest 2004;113:651–7.
  • 6.Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab 2015;66(Suppl 1):8–16.
  • 7.Yosipovitch G and Papoiu A. Curr Allergy Asthma Rep 2008;8:306–11.
  • 8.American Academy of Dermatology. The layers of your skin. Available at www.aad.org/public/kids/skin/the-layers-of-your-skin (accessed June 2020).
  • 9.Watson W and Kapur S. Atopic dermatitis. Allergy Asthma Clin Immunol 2011; 7(Suppl 1):S4.
  • 10.Hong J et al. Management of Itch in Atopic Dermatitis. Semin Cutan Med Surg 2011; 30(2): 71–86.
  • 11.Zuberbier T et al. Patient perspectives on the management of atopic dermatitis. J Allergy Clin Immunol 2006;118(1):226–32.
  • 12.Slattery MJ et al. Depression, anxiety, and dermatologic quality of life in adolescents with atopic dermatitis. J Allergy Clin Immunol 2011;128(3):668–71.e3.
  • 13.Ridgeway JL et al. A brief patient-reported outcomes quality of life (PROQOL) instrument to improve patient care. PLoS Med 2013;10(11):e1001548.
  • 14.Lifschitz C. The impact of atopic dermatitis on quality of life. Ann Nutr Metab 2015;66 Suppl 1:34–40.
  • 15.Australasian Society of Clinical Immunology and Allergy (ASCIA). Factsheet: Eczema (atopic dermatitis). ASCIA 2015.
  • 16.Neff KD et al. Self-compassion and adaptive psychological functioning. J Res Pers 2007; 41:139–154.
  • 17.Sutherland O et al. Conversation analysis of the two-chair self-soothing task in emotion-focused therapy. Psychother Res 2014;24(6):738–51.
  • 18.Wollenberg A et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol 2018;32(5):657–82.
  • 19.Wollenberg A et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol 2018;32(6):850–78.
  • 20.Nguyen TV et al. Compassionate care: enhancing physician-patient communication and education in dermatology: part I: patient-centered communication. J Am Acad Dermatol 2013;68(3):353.e1–8.
  • 21.Mann T et al. Self-regulation of health behavior: social psychological approaches to goal setting and goal striving. Health Psychol 2013;32(5):487–98.
  • 22.Lio PA et al. Clinical management of atopic dermatitis: practical highlights and updates from the atopic dermatitis practice parameter 2012. J Allergy Clin Immunol Pract 2014;2(4):361–9;quiz 370.
  • 23.Fried RG and Hussain SH. Nonpharmacologic management of common skin and psychocutaneous disorders. Dermatol Ther 2008;21(1):60–8.
  • 24.Leibovici V et al. Effects of virtual reality immersion and audiovisual distraction techniques for patients with pruritus. Pain Res Manag 2009;14(4):283–6.
  • 25. Rodrigues MA and Torres T. The changing landscape of atopic dermatitis – focusing on JAK inhibitors. Eur Ann Allergy Clin Immunol 2020;52:45–8.
  • 26. European Medicines Agency. New oral treatment for moderate to severe atopic dermatitis. 2020. Available at www.ema.europa.eu/en/news/new-oral-treatment-moderate-severe-atopic-dermatitis (accessed August 2022).
  • 27. Cotter DG et al. Emerging therapies for atopic dermatitis: JAK inhibitors. J Am Acad Dermatol 2018;78:S53–62.